T cell receptor bispecific agents provide off-the-shelf therapies for targeting intracellular tumor antigens.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The physiological interactome of TCR-like antibody therapeutics in human tissues
Nature Communications Open Access 16 April 2024
-
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Nature Cancer Open Access 02 October 2023
-
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
Scientific Reports Open Access 31 March 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. First soluble TCR therapy opens ‘new universe’ of cancer targets. Nat Biotechnol 40, 441–444 (2022). https://doi.org/10.1038/s41587-022-01282-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01282-6
This article is cited by
-
The physiological interactome of TCR-like antibody therapeutics in human tissues
Nature Communications (2024)
-
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
Scientific Reports (2023)
-
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Nature Cancer (2023)